The US equities are trying to deal with so much liquidity and an extreme bullish sentiment that we are just sloshing and whooshing. Good for traders. I doubt a change is far in the future. Earnings and outlooks will eventually ground the market to some degree.
Data strategy is a cornerstone of business viability in health technology. How you solidify and communicate a comprehensive data strategy can help you realize growth, generate revenue, and create investor interest.
Activity is slowing down and continuation patterns proliferate. NDX is more bullish than SPX. SPX sectors are sideways to mild correction except XLK, XLY +/- XLV. It’s time to let 2020 be – sans a new disaster. Enjoy the season and come back to it in 2021.
There has been an explosion of digital health innovation in clinical trials. The Rock Health Consulting team explores this evolution and what the next horizon will bring to clinical trials.
Momentum declined last week and with net bullish sentiment is not a great setup for further gains short term. The indexes are overbought but not excessively so and appear to be internally correcting. The peak may have coincided with the two IPO’s this week that were extreme. Next market movers: momentum + pandemic + earnings.
Last week was very bullish for stocks. We are reaching the tops of technical ranges but have not yet established extreme overbought conditions, which as we all know can last for long periods especially in raging momentum markets like what we have now. If “raging” was a stock it would be ripe for a correction.
By providing your contact information you consent to receiving emails & information from Green Room Technologies.
No Spam. We respect your privacy & you may unsubscribe at any time.